This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

EVENT: Imaging Membrane Proteins in Real Time

EVENT: Imaging Membrane Proteins in Real Time

26 Nov 2024

Come along to an event hosted by Sitryx to hear expert insights from The Kennedy Insitute of Rheumatology and The Rosalind Franklin Institute. Read more

Theolytics doses first patient in trial to treat ovarian cancer

Theolytics doses first patient in trial to treat ovarian cancer

26 Nov 2024

Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC). Ovarian Cancer is one of the leading causes of cancer related deaths among women. It exhibits a stromal rich, immune-suppressed TME,... Read more

EIT Oxford at The Oxford Science Park

EIT Oxford at The Oxford Science Park

07 Nov 2024

We recently spoke to Lisa Flashner, COO of EIT Oxford, about why a leading medical research and development centre in California chose The Oxford Science Park as the location for its European campus. Proximity to the world’s leading university and world-class research institutions; access to great minds and scientific discovery; a thriving, collaborative innovation community; and the availability of high-spec laboratory space are all reasons... Read more

Video highlights from launch of The Daubeny Project

Video highlights from launch of The Daubeny Project

15 Oct 2024

Last month The Oxford Science Park (TOSP) hosted an event to formally launch The Daubeny Project, a 450,000 sq ft development of premium lab space currently under construction at TOSP. The event brought together leaders from the life sciences industry, Oxford’s universities, and key figures from the city’s innovation ecosystem to discuss ways to leverage Oxford’s strengths in collaboration. A key theme was the importance of creating... Read more

Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

03 Oct 2024

Enara Bio has raised $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. The round was co-led by new investors, Pfizer Ventures and M Ventures, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health Investors. The Francis Crick Institute is also joining the round as a new investor. Enara Bio will use the proceeds to advance its pipeline of... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More